CYP4B1 inhibits lung adenocarcinoma progression via PI3K/AKT/mTOR pathway: mechanistic insights and development of a CYP4B1-related prognostic signature

Guoyin Li, Jing Kang, Xiaoyan Li, Liping Zhao, Yuhang Chen, Chenlu Gong, Zhiqiang Liu, Bi Zhang · 2026

Read CYP4B1 inhibits lung adenocarcinoma progression via PI3K/AKT/mTOR pathway: mechanistic insights and development of a CYP4B1-related prognostic signature by Guoyin Li, Jing Kang, Xiaoyan Li, Liping Zhao, Yuhang Chen, Chenlu Gong, Zhiqiang Liu, Bi Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12883422.txt.

Description

Guoyin Li and co-authors make the case that a lung enzyme most doctors ignore is quietly fighting the commonest lung cancer. CYP4B1, concentrated in lung tissue, runs low in lung adenocarcinoma, and patients with more of it live longer. Lab and animal experiments showed the enzyme slowing tumor growth by damping the PI3K/AKT/mTOR growth pathway.

The team also found its upstream switch: the transcription factor NFIA binds the gene's promoter and turns it on. From seven CYP4B1-related genes they built a risk score that split patients into groups with clearly different survival in training and validation cohorts, and tied into drug sensitivity. A nomogram adding clinical variables predicted one, three, and five year survival respectably. Translation to the clinic awaits, the authors caution.

Catalog record

CREATORGuoyin Li, Jing Kang, Xiaoyan Li, Liping Zhao, Yuhang Chen, Chenlu Gong, Zhiqiang Liu, Bi Zhang
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12883422

Browse the full library · About the Tower of Babel